164119-81-7Relevant articles and documents
Discovery of a lead series of potent benzodiazepine 5-HT2C receptor agonists with high selectivity in functional and binding assays
Dang, Huong,Feichtinger, Konrad,Frazer, John,Grottick, Andrew J.,Kasem, Michelle,Le, Minh,Lehman, Juerg,Morgan, Michael E.,Ren, Albert,Sage, Carleton R.,Schrader, Thomas O.,Semple, Graeme,Unett, David J.,Whelan, Kevin T.,Wong, Amy,Zhu, Xiuwen
supporting information, (2020/01/22)
A series of potential new 5-HT2 receptor scaffolds based on a simplification of the clinically studied, 5-HT2CR agonist vabicaserin, were designed. An in vivo feeding assay early in our screening process played an instrumental part in the lead identification process, leading us to focus on a 6,5,7-tricyclic scaffold. A subsequent early SAR investigation provided potent agonists of the 5-HT2C receptor that were highly selective in both functional and binding assays, had good rat PK properties and that significantly reduced acute food intake in the rat.
5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE
-
Page/Page column 199, (2015/05/19)
Provided are 5-HT2C receptor agonists. Also provided are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided are compositions comprising a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent, and methods for reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reducing weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use comprising administering a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent.
CHYMASE INHIBITORS
-
Page/Page column 25-26, (2010/04/03)
Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase (formula I). Also disclosed are pharmaceutical compositions, methods of using and making the same.
HYDRAZONE COMPOUNDS AND THEIR USE
-
Page/Page column 104-105, (2010/12/17)
The present invention relates to hydrazone compounds of Formula I: (I) and pharmaceutically acceptable salts and stereoisomers thereof, wherein R1, R2, R3, R4, L1, and L2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I as inhibitors of TRPM5 protein.
Synthesis and biological activities of 4-trifluoromethylindole-3-acetic acid: A new fluorinated indole auxin
Katayama, Masato,Masui, Yuko,Kageyama, Eiji,Kawabata, Youichi,Kanayama, Kozo
, p. 2025 - 2033 (2008/12/22)
In our studies on the development of new promoters for the root formation of tree cuttings, 4-trifluoromethylindole-3-acetic acid (4-CF3-IAA), a new fluorinated auxin, was synthesized via 4-trifluoromethylindole and 4-trifluoromethylindole-3-acetonitrile by using 2-methyl-3-nitrobenzotrifluoride as the starting material. As a control compound for comparing biological activities, 4-methylindole-3-acetic acid (4-CH3-IAA) was also synthesized by using 2,3-dimethylnitrobenzene as the starting material. The biological activities of these compounds were compared by three bioassays with those of indole-3-acetic acid and 4-chloroindole-3-acetic acid (4-Cl-IAA), which, like 4-CF3-IAA and 4-CH3-IAA, has a substituent at the 4-position of the indole nucleus. 4-CF3-IAA showed strong root formation-promoting activity with black gram cuttings which was 1.5 times higher than that of 4-(3-indole)butyric acid at 1 × 10-4 M. 4-CH 3-IAA, however, only weakly promoted root formation in spite of its strong inhibition of hypocotyl growth in Chinese cabbage and promotion of hypocotyl swelling and lateral root formation in black gram. On the other hand, 4-CF3-IAA demonstrated weaker activities than 4-CH3-IAA and 4-Cl-IAA in these two bioassays.
Synthesis of enantiomerically pure 4-alkylsubstituted tryptophan derivatives by a combination of organometallic reactions with enantioselective enzymatic transformations
Nettekoven, Matthias,Psiorz, Manfred,Waldmann, Herbert
, p. 1425 - 1428 (2007/10/02)
The synthesis of enantiomerically pure 4-substituted tryptophans 12 is described. Key steps are i) the introduction of an alkyl substituent into the 4-position of the indole via regioselective lithiation of N-TIPS protected gramine and ii) the enantioselective saponification of the phenyl acetamides of 4-substituted tryptophans by the enzyme penicillin G acylase.
